Observational studyPediatric nephrology (Berlin, Germany)2022
Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
Observational study in Pediatric nephrology (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- B cell depletion with rituximab in children with steroid-sensitive nephrotic syndrome: does depletion duration change outcome?Pediatric nephrology (Berlin, Germany) · 2026Article
- Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Subcutaneous ofatumumab for remission maintenance in pediatric idiopathic nephrotic syndrome: a case series.Clinical kidney journal · 2026Article
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Cyclophosphamide Plus Rituximab Versus Cyclophosphamide in Antineutrophil Cytoplasmic Antibody-associated Vasculitis With Kidney Involvement: A Retrospective Cohort Study in China.Kidney medicine · 2026Article
- Podocytopathies.Nature reviews. Disease primers · 2025Review
- Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.Clinical and experimental nephrology · 2025Article
- Parental perspectives on the effectiveness and safety of rituximab in treating pediatric nephrotic syndrome: a nationwide multi-center survey study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes.Clinical immunology communications · 2025Article
- Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up.Frontiers in immunology · 2025Article
- Secondary antibody deficiencies: what's around the corner?Frontiers in immunology · 2025Review
- Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome.Clinical and experimental nephrology · 2024Article
- Association between Infection and Calculated Globulin Level among Patients with Thymic Epithelial Tumor.Journal of clinical medicine · 2024Article
- Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Infection Risk, Mortality, and Hypogammaglobulinemia Prevalence and Associated Factors in Adults Treated with Rituximab: A Tertiary Care Center Experience.Clinics and practice · 2023Article
- Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.Pediatric nephrology (Berlin, Germany) · 2023Article
- Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypogammaglobulinemia is a major adverse event after rituximab treatment; however, the precise incidence and risk factors are unclear in complicated steroid-dependent or frequently relapsing nephrotic syndrome (SDNS/FRNS) patients.
methodsThis was a single-center, retrospective, observational study. Patients who received a single dose of rituximab for complicated SDNS or FRNS between February 2007 and May 2019 were enrolled. Serum IgG levels were plotted, and their trends were evaluated after rituximab treatment. The incidence of transient and persistent hypogammaglobulinemia was examined, and risk factors were calculated by multivariate analysis using logistic regression.
resultsWe enrolled 103 patients who received 238 single doses of rituximab. Hypogammaglobulinemia was observed in 58.4% of the patients at least once after a single dose of rituximab treatment and 22.3% developed persistent hypogammaglobulinemia. Serum IgG levels gradually increased during B-cell depletion, and patients with low serum IgG levels at rituximab treatment had persistent hypogammaglobulinemia. Repeated courses of rituximab treatment increased the incidence of hypogammaglobulinemia. A past history of steroid-resistant nephrotic syndrome (SRNS) (odds ratio [OR] = 10.02; 95% confidence interval [CI] = 2.65-37.81; P < 0.001) and low serum IgG levels at rituximab treatment (OR = 7.63; 95% CI = 2.10-27.71; P = 0.002) was significantly associated with hypogammaglobulinemia in multivariate analysis.
conclusionsHypogammaglobulinemia is a frequent adverse event after rituximab treatment, although IgG levels slightly increase during B-cell depletion. Low serum IgG levels at rituximab treatment and a past history of SRNS are significant risk factors for the development of hypogammaglobulinemia after rituximab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.